Skip to content
DataLookout
Menu

NCT04684459

Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

StatusUnknown
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary completion date: Dec 30, 2024 to Dec 30, 2025
    • Eligibility criteria expanded, about 50 words
    • Study title shortened, about 4 words
    v5
  3. Notable Primary completion date: Jan 1, 2023 to Dec 30, 2024
    • Study completion date: Jan 1, 2024 to Dec 30, 2025
    v4
  4. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v3
  5. Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Jan 1, 2021 to Mar 12, 2021
    • Site contact updated
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Treatment-Related Adverse Events
Timeframe: 12 months
Dose-limiting toxicity (DLT)
Timeframe: 12 months

Secondary (2)

ORR(objective response rate)
DOR (duration of response)

Arms and interventions

CAR-T cell therapyExperimental

Dual-targeting HER2 and PD-L1 CAR-T cell therapy

Biologicals: Dual-targeting HER2 and PD-L1 CAR-T cells

Sites

1 site in 1 country

  • West China Hospital, Sichuan UniversityChengdu, Sichuan, China